• NICE nod for Blincyto pharmatimes
    June 19, 2019
    The National Institute for Health and Care Excellence (NICE) has announced the recommendation of Amgen’s Blincyto (blinatumomab) for treating acute lymphoblastic leukaemia (ALL). The indication is for patients in first complete remission with minimal resi
  • Samsung Bioepis gets nod for sale of biosimilar drug in Europe firstwordpharma
    March 06, 2019
    Samsung Bioepis has won European approval of a 420-mg dosage of Ontruzant, a biosimilar of Roche's Herceptin, The Korea Herald reported Tuesday.
  • Roche's Genentech to acquire inflammatory drug discovery firm Jecure pharmafile
    November 30, 2018
    Roche’s subsidiary Genentech has finalised a definitive agreement to acquire Jecure, a US-based biotech which focuses on the discovery of drugs to treat serious inflammatory conditions, in a bid to square up to rivals in the treatment of fatty liver disea
  • Roche's Genentech to acquire inflammatory drug discovery firm Jecure pharmafile
    November 29, 2018
    Roche’s subsidiary Genentech has finalised a definitive agreement to acquire Jecure, a US-based biotech which focuses on the discovery of drugs to treat serious inflammatory conditions...
PharmaSources Customer Service